Aernoud Fiolet

68 Chapter 2 20. M. Nasiri, A. Janoudi, A.F.M. Vanderberg, C. Flegler, S. Flegler, G.S. Abela. Role of cholesterol crystals in atherosclerosis is unmasked by altering tissue preparation methods. Microsc Res Tech, 78 (2015), pp. 969-974 21. R. Patel, A. Janoudi, A. Vedre, et al. Plaque rupture and thrombosis is reduced by lowering cholesterol levels and crystallization with ezetimibe and is correlated with FDG-PET. Arterioscler Thromb Vasc Biol, 31 (2011), pp. 2007-2014 22. N. Varsano, F. Beghi, N. Elad, et al. Two polymorphic cholesterol monohydrate crystal structures form in macrophage culture models of atherosclerosis. Proc Natl Acad Sci, 115 (2018), pp. 7662- 7669 23. M.C. Carey, D.M. Small. The physical chemistry of cholesterol solubility in bile. J Clin Invest, 61 (1978), pp. 998-1026 24. S.S. Katz, D.M. Small. Isolation and partial characterization of the lipid phases of human atherosclerotic plaques. J Biol Chem, 255 (1980), pp. 9753-9759 25. S.S. Katz, G.G. Shipley, D.M. Small. Physical chemistry of the lipids of human atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and advanced plaques. J Clin Invest, 58 (1976), pp. 200-211 26. N. Kessler, D. Perl-Treves, L. Addadi, M. Eisenstein. Structural and chemical complementarity between antibodies and the crystal surfaces they recognize. Proteins, 34 (1999), pp. 383-394 27. E. Zimmerman, L. Addadi, B. Geiger. Effects of surface-bound water and surface stereochemistry on cell adhesion to crystal surfaces. J Struct Biol, 125 (1999), pp. 25-38 28. E.O. Samstad, N. Niyonzima, S. Nymo, et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol, 192 (2014), pp. 2837-2845 29. M. Doherty, J.T. Whicher, P.A. Dieppe. Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles. Ann Rheum Dis, 42 (1983), pp. 285-291 30. D. Perl-Treves, N. Kessler, D. Izhaky, L. Addadi. Monoclonal antibody recognition of cholesterol monohydrate crystal faces. Chem Biol, 3 (1996), pp. 567-577 31. G.M. Swartz, M.K. Gentry, L.M. Amende, E.J. Blanchette-Mackie, C.R. Alving. Antibodies to cholesterol. Proc Natl Acad Sci, 85 (2006), pp. 1902-1906 32. P.Hasselbacher,J.L.Hahn.Activationof the alternativepathwayof complement bymicrocrystalline cholesterol. Atherosclerosis, 37 (1980), pp. 239-245a. Phinikaridou, K.J. Hallock, Y. Qiao, J.A. Hamilton. A robust rabbit model of human atherosclerosis and atherothrombosis. J Lipid Res, 50 (2009), pp. 787-797 33. Y. Baumer, S. McCurdy, X. Jin, et al. Ultramorphological analysis of plaque advancement and cholesterol crystal formation in Ldlr knockout mouse atherosclerosis. Atherosclerosis, 287 (2019), pp. 100-111 34. P. Holvoet. Endothelial dysfunction, oxidation of low-density lipoprotein, and cardiovascular disease. Ther Apher, 3 (1999), pp. 287-293 35. Y. Baumer, S. McCurdy, T.M. Weatherby, et al. Hyperlipidemia-induced cholesterol crystal production by endothelial cells promotes atherogenesis. Nat Commun, 8 (2017), p. 1129 36. S.M. Krishnan, C.G. Sobey, E. Latz, A. Mansell, G.R. Drummond. IL-1 β and IL-18: inflammatory markers or mediators of hypertension? Br J Pharmacol, 171 (2014), pp. 5589-5602 37. J.P. Green, C. Souilhol, I. Xanthis, et al. Atheroprone flow activates inflammation via endothelial ATP-dependent P2X7-p38 signalling. Cardiovasc Res, 114 (2018), pp. 324-335